Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Clinical Trials
288
Trial Phases
6 Phases
Drug Approvals
3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (287 trials with phase data)• Click on a phase to view related trials
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: TQB3201 tablets
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 291
- Registration Number
- NCT07172126
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Chongqing University, Chongqing, Chongqing Municipality, China
🇨🇳The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
🇨🇳Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: TQC3721 Suspension for inhalationDrug: Placebo of TQC3721 Suspension for Inhalation
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 666
- Registration Number
- NCT07147946
- Locations
- 🇨🇳
Bozhou People's Hospital, Bozhou, Anhui, China
🇨🇳Chizhou People's Hospital, Chizhou, Anhui, China
🇨🇳Chaohu Hospital of Anhui Medical University, Hefei, Anhui, China
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Drug: TQB3473 Tablets
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT07083739
- Locations
- 🇨🇳
The first affiliated hospital of ustc anhui provincial hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
- Conditions
- Myeloid Malignancy
- Interventions
- Drug: TQB3909 Tablets + Azacitidine
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT07011186
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 215
- Registration Number
- NCT06990776
- Locations
- 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 58
- Next